Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug884 | ChAdOx1 nCoV-19 0.5mL prime plus boost Wiki | 0.71 |
| drug4192 | VXA-CoV2-1 Wiki | 0.71 |
| drug4101 | Two dose MenACWY vaccine Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug881 | ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Wiki | 0.71 |
| drug880 | ChAdOx1 nCoV-19 (Abs 260) Wiki | 0.71 |
| drug4102 | Two dose MenACWY vaccine min. 4 weeks apart Wiki | 0.71 |
| drug2333 | MenACWY vaccine Wiki | 0.71 |
| drug890 | ChAdox1 n-CoV-19 (Abs 260) vaccine low dose Wiki | 0.71 |
| drug882 | ChAdOx1 nCoV-19 (qPCR) Wiki | 0.71 |
| drug2916 | Placebo Wiki | 0.06 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.05 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
This is a study to evaluate the effectiveness and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in a minimum of approximately 2,960 to a maximum of approximately 4,164 healthy HIV-negative (HIV-) adult participants and in approximately 240 medically stable HIV-positive (HIV+) adult participants in up to 15 sites across South Africa. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in these study populations. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study.
Description: Number of human immunodeficiency virus negative (HIV-) participants with first occurrence of positive (+) polymerase chain reaction (PCR), (+) PCR-confirmed, SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19 assessed from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Cohort 1: HIV- Participants with Symptomatic Mild, Moderate, or Severe COVID-19 Time: Day 28 to Day 386Description: Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic moderate or severe COVID-19 assessed from Day 28 (7 days after second vaccination) through the length of the study.
Measure: Cohort 1: HIV- Participants with Symptomatic Moderate or Severe COVID-19 Time: Day 28 to Day 386Description: Numbers and percentages (with 95% confidence intervals [CIs]) of HIV- participants with solicited AEs, local and systemic, for 7 days following each vaccination (Days 0 and 21) by severity score, duration, and peak intensity.
Measure: Cohort 1: HIV- Participants with Solicited Adverse Events (AEs) Time: 28 daysDescription: Numbers and percentages (with 95% CI) of HIV- participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, MAAEs) through Day 35 by Medical Dictionary for Regulatory Activities (MedDRA) classification, severity score, and relatedness.
Measure: Cohort 1: HIV- Participants with Unsolicited AEs Time: 35 daysDescription: Numbers and percentages (with 95% CIs) of HIV+ participants with solicited AEs, local and systemic, for 7 days following each vaccination (Days 0 and 21) by severity score, duration, and peak intensity.
Measure: Cohort 2: HIV+ Participants with Solicited AEs Time: 28 daysDescription: Numbers and percentages (with 95% CI) of HIV+ participants with unsolicited AEs (eg, treatment-emergent, serious, suspected unexpected serious, those of special interest, MAAEs) through Day 35 by MedDRA classification, severity score, and relatedness.
Measure: Cohort 2: HIV+ Participants with Unsolicited AEs Time: 35 daysDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Day 35.
Measure: Cohort 2: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as Geometric Mean Titers (GMTs) Time: Day 35Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Day 35.
Measure: Cohort 2: Serum IgG Antibody Levels Expressed as Geometric Mean Fold Rises (GMFRs) Time: Day 35Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCR at Day 35. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre existing titer.
Measure: Cohort 2: Serum IgG Antibody Levels Expressed as Seroconversion Rates (SCRs) Time: Day 35Description: Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness in terms of individual strata of symptomatic virologically confirmed, mild, moderate, or severe COVID-19.
Measure: Cohort 1: HIV- Participants with Individual Strata of Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19 Time: Day 28 to Day 386Description: Number of HIV- participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with COVID-19 requiring hospitalization.
Measure: Cohort 1: HIV- Participants with COVID-19 Requiring Hospitalization Time: Day 28 to Day 386Description: Incidence, maximum severity score, and symptom duration of SARS-CoV-2 infection by classification of symptomatic virologically confirmed, mild, moderate, and/or severe disease in HIV- participants.
Measure: Cohort 1: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification Time: Day 28 to Day 386Description: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV- participants. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre-existing titer.
Measure: Cohort 1: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: Angiotensin-Converting Enzyme 2 (ACE2) Receptor Binding Inhibition Assay Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SRRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants. SRR is defined as the proportion of participants with rises in titers exceeding the 95th percentile of placebo participants at the same time point and based on prior SARS-CoV-2 exposure.
Measure: Cohort 1: ACE2 Receptor Binding Inhibition Assay Expressed as Seroresponse Rates (SRRs) Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: Neutralizing Antibody Activity Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as GMFRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV-participants.
Measure: Cohort 1: Neutralizing Antibody Activity Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as SCRs (≥ 4 fold change) at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV- participants.
Measure: Cohort 1: Neutralizing Antibody Activity Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as SRRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV-participants.
Measure: Cohort 1: Neutralizing Antibody Activity Expressed as SRRs Time: Day 0 to 6 months after the last vaccinationDescription: Numbers and percentages (with 95% CI) of participants with MAAEs, AESI, or SAE through End of Study by MedDRA classification, severity score, and relatedness in HIV- participants.
Measure: Cohort 1: HIV- Participants with Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), and Serious Adverse Events (SAEs) Time: 386 daysDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Serum IgG antibody levels specific for the SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as SCRs at Days 0 (baseline), 21 (post first dose), and at 3 and 6 months after the last vaccination in HIV+ participants. SCR is defined as the percentage of participants with a post-vaccination titer ≥ 4 fold over naïve background and ≥ 2 fold over pre-existing titer.
Measure: Cohort 2: Serum IgG Antibody Levels at Multiple Time Points Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMTs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as GMFRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SCRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by ACE2 receptor binding inhibition assay expressed as SRRs at Days 0 (baseline), 21 (post first dose), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants. SRR is defined as the proportion of participants with rises in titers exceeding the 95th percentile of placebo participants at the same time point and based on prior SARS-CoV-2 exposure.
Measure: Cohort 2: ACE2 Receptor Binding Inhibition Assay Expressed as SRRs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN as expressed as GMTs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Neutralizing Antibody Activity Expressed as GMTs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as GMFRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Neutralizing Antibody Activity Expressed as GMFRs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as SCRs (≥ 4 fold change) at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Neutralizing Antibody Activity Expressed as SCRs Time: Day 0 to 6 months after the last vaccinationDescription: Neutralizing antibody activity as detected by MN expressed as SRRs at Days 0 (baseline), 35 (post second dose), and at 3 and 6 months after the last vaccination in HIV+ participants.
Measure: Cohort 2: Neutralizing Antibody Activity Expressed as SRRs Time: Day 0 to 6 months after the last vaccinationDescription: Numbers and percentages (with 95% CI) of participants with MAAEs, AESI, or SAE through End of Study by MedDRA classification, severity score, and relatedness in HIV+ participants.
Measure: Cohort 2: HIV+ Participants with MAAEs, AESIs, and SAEs Time: 386 daysDescription: Counts and proportions of symptomatic virologically confirmed, mild, moderate, and severe COVID-19 outcomes in HIV+ participants as previously described in the second primary efficacy endpoint for Cohort 1 (HIV- participants).
Measure: Cohort 2: HIV+ Participants with Symptomatic Virologically Confirmed, Mild, Moderate, or Severe COVID-19 Time: Day 28 to Day 385Description: Incidence, maximum severity score, and symptom duration of SARS-CoV-2 infection by classification of symptomatic virologically confirmed, mild, moderate, and/or severe disease in HIV+ participants.
Measure: Cohort 2: Incidence, Maximum Severity Score, and Symptom Duration of SARS-CoV-2 Infection by Severity Classification Time: Day 28 to Day 385This is a study to evaluate the effectiveness, immune response, and safety of a coronavirus disease 2019 (COVID-19) vaccine called SARS-CoV-2 rS with Matrix-M1 adjuvant in adults 18 years of age and older in the United States and Mexico. A vaccine causes the body to have an immune response that may help prevent the infection or reduce the severity of symptoms. An adjuvant is something that can make a vaccine work better. This study will look at the protective effect, body's immune response, and safety of SARS-CoV-2 rS with Matrix-M1 adjuvant in the study population. Participants in the study will randomly be assigned to receive SARS-CoV-2 rS with Matrix-M1 adjuvant or placebo. Each participant in the study will receive a total of 2 intramuscular injections over the course of the study. Up to 30,000 participants will take part in the study.
Description: Number of participants with first occurrence of positive (+) polymerase chain reaction (PCR)-confirmed SARS-CoV-2 illness with symptomatic mild, moderate, or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic Mild, Moderate, or Severe Coronavirus Disease 2019 (COVID-19) Time: Day 28 to Day 750Description: Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with symptomatic moderate or severe COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Symptomatic Moderate or Severe COVID-19 Time: Day 28 to Day 750Description: Number of participants with first occurrence of (+) PCR-confirmed SARS-CoV-2 illness with any symptomatic COVID-19, with each symptom lasting for at least 2 consecutive days, with onset from Day 28 (7 days after second vaccination dose) through the length of the study.
Measure: Participants with Any Symptomatic COVID-19 Time: Day 28 to Day 750Description: Neutralizing antibody activity as detected by microneutralization assay (MN) as expressed as GMTs at Days 0, 35 and Month 3.
Measure: Neutralizing Antibody Activity Expressed as Geometric Mean Titers (GMTs) Time: Day 0 to Day 105Description: Neutralizing antibody activity as detected by MN as expressed as GMFRs at Days 0, 35 and Month 3.
Measure: Neutralizing Antibody Activity Expressed as Geometric Mean Fold Rises (GMFRs) Time: Day 0 to Day 105Description: Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by enzyme-linked immunosorbent assay (ELISA) expressed as GMTs at Days 0, 35 and Month 3.
Measure: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs Time: Day 0 to Day 105Description: Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Days 0, 35 and Month 3.
Measure: Serum IgG Antibody Levels Expressed as GMFRs Time: Day 0 to Day 105Description: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Days 0, 35 and Month 3.
Measure: Human Angiotensin-Converting Enzyme 2 (hACE2) Receptor Binding Inhibition Assay Expressed as GMTs Time: Day 0 to Day 105Description: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Days 0, 35 and Month 3.
Measure: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs Time: Day 0 to Day 105Description: Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMTs at Months 6, 12, 18, and 24.
Measure: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMTs at Later Time Points Time: Day 165 to Day 750Description: Serum IgG antibody levels specific to SARS-CoV-2 rS protein antigen(s) as detected by ELISA expressed as GMFRs at Months 6, 12, 18, and 24.
Measure: Serum Immunoglobulin G (IgG) Antibody Levels Expressed as GMFRs at Later Time Points Time: Day 165 to Day 750Description: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMTs at Months 6, 12, 18, and 24.
Measure: hACE2 Receptor Binding Inhibition Assay Expressed as GMTs at Later Time Points Time: Day 165 to Day 750Description: Epitope-specific immune responses to the SARS-CoV-2 rS protein receptor binding as detected by hACE2 receptor binding inhibition assay expressed as GMFRs at Months 6, 12, 18, and 24.
Measure: hACE2 Receptor Binding Inhibition Assay Expressed as GMFRs at Later Time Points Time: Day 165 to Day 750Description: Neutralizing antibody activity as detected by MN as expressed as GMTs at Months 6, 12, 18, and 24.
Measure: Neutralizing Antibody Activity Expressed as GMTs at Later Time Points Time: Day 165 to Day 750Description: Neutralizing antibody activity as detected by MN as expressed as GMFRs at Months 6, 12, 18, and 24.
Measure: Neutralizing Antibody Activity Expressed as GMFRs at Later Time Points Time: Day 165 to Day 750Description: Description of course, treatment and severity of COVID-19 reported after a PCR-confirmed case via the Endpoint Form.
Measure: Description of Course, Treatment and Severity of COVID-19 Time: Day 28 to Day 750Description: Reactogenicity incidence and severity (mild, moderate or severe) recorded by all participants on their electronic patient-reported outcome diary application (eDiary) on days of vaccination and subsequent 6 days (total 7 days after each vaccine injection).
Measure: Reactogenicity Incidence and Severity Time: Day 0 to Day 27Description: Number of participants with mild, moderate, or severe MAAEs through Day 49.
Measure: Incidence and Severity of Medically Attended Adverse Events (MAAEs) Through Day 49. Time: Day 0 to Day 49Description: Number of participants with mild, moderate, or severe AEs through Day 49.
Measure: Incidence and Severity of Unsolicited Adverse Events (AEs) Through Day 49. Time: Day 0 to Day 49Description: Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine through Month 12.
Measure: Incidence and Severity of MAAEs Attributed to Study Vaccine Through Month 12. Time: Day 0 to Day 375Description: Number of participants with mild, moderate, or severe SAEs through Month 12.
Measure: Incidence and Severity of Serious Adverse Events (SAEs) Through Month 12. Time: Day 0 to Day 375Description: Number of participants with mild, moderate, or severe AESIs through Month 12.
Measure: Incidence and Severity of Adverse Events of Special Interest (AESIs) Through Month 12. Time: Day 0 to Day 375Description: Number of participants with mild, moderate, or severe SAEs from Month 12 to Month 24.
Measure: Incidence and Severity of SAEs from Month 12 to Month 24. Time: Day 360 to Day 750Description: Number of participants with mild, moderate, or severe MAAEs attributed to study vaccine from Month 12 to Month 24.
Measure: Incidence and Severity of MAAEs Attributed to Study Vaccine from Month 12 to Month 24. Time: Day 360 to Day 750Description: Number of participants with mild, moderate, or severe AESIs attributed to study vaccine from Month 12 to Month 24.
Measure: Incidence and Severity of AESIs from Month 12 to Month 24. Time: Day 360 to Day 750Description: Number of participants who died during the study due to any cause.
Measure: Deaths Due to Any Cause Time: Day 0 to Day 750Description: Number of participants with antibodies to SARS-CoV-2 NP at Days 0 and 35, or Months 3, 6, 12, 18 and 24 to determine natural infection and to determine the incidence of asymptomatic infection acquired during study follow-up.
Measure: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Specific Time Points Time: Day 0 to Day 750Description: Number of participants with antibodies to SARS-CoV-2 NP, regardless of whether the infection was symptomatic.
Measure: Antibodies to SARS-CoV-2 Nucleoprotein (NP) at Any Time Point Time: Day 0 to Day 750Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports